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Abstract
Background: Juvéderm Voluma XC is a volumizing hyaluronic acid filler used for correction of age-related midface volume deficit (MVD).
Objectives: The effectiveness of Juvéderm Voluma XC was examined from the patient perspective.
Methods: Patients with moderate to severe age-related MVD (N = 235) received Juvéderm Voluma XC. At quarterly follow-up visits for 2 years, patients
rated treatment outcomes on the Global Aesthetic Improvement Scale (GAIS), overall satisfaction with facial appearance, satisfaction with midfacial regions,
achievement of treatment goal, Look and Feel of the Midface (LAFM), and Self-Perception of Age (SPA). Patients recorded treatment-site responses in 30-
day diaries.
Results: At 6 months and 2 years after treatment, 92.8% and 79.0% of patients, respectively, rated their cheek volume as improved/much improved on
the GAIS. Improvement in satisfaction with facial appearance was noted by 89.8% of patients at 6 months and 75.8% at 2 years. Increased satisfaction with
outer and lower cheek areas and cheek-bone projection and clinically significant improvements in LAFM were noted through month 24. Treatment goals
were achieved by 67.8% of patients at 6 months and 49.0% at 2 years. Patients reported looking, on average, 5 years younger at 6 months and 3 years
younger at 2 years. The most common treatment site responses were tenderness, swelling, firmness, and lumps/bumps; most were mild to moderate in
severity and lasted ≤2 weeks.
Conclusions: Juvéderm Voluma XC for age-related MVD is effective and well-tolerated from the patient perspective, with results lasting up to 2 years.
Level of Evidence: 4
TherapeuticAccepted for publication October 16, 2014; online publish-ahead-of-print May 11, 2015.
Visible signs of facial aging result, in part, from the loss of
structural support over time. As the midface ages, volume
loss occurs in the skin, bone, muscle, and superficial and
deep fat.1-6 Volume loss of deep midfacial fat reduces
support for the medial cheek compartment, diminishing
projection of the midface.1,2 Gravity, coupled with volume
loss of buccal fat, results in inferior migration of fat com-
partments, leading to deepening of the nasojugal fold and
development of a crescent-shaped hollow beneath the lower
edge of the orbicularis oculi muscle.4 In addition, the suspen-
sory ligaments elongate, resulting in a lowering of the
malar fat pad and cheek skin.7,8 Tonal changes to individual
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muscles and changes in skin quality, such as the develop-
ment of wrinkles and drooping skin, may also contribute to
the appearance of aging.9,10
Nonsurgical aesthetic procedures, such as those aimed
at restoring volume to the midface, are voluntary; therefore,
patient satisfaction is critical for evaluating treatment effec-
tiveness.11 In studies of facial aesthetics, outcomes that
measure factors such as patient satisfaction, perception of
overall aesthetic change, and impact on quality of life are key
components. In addition to directly assessing patient satisfac-
tion, such outcomes measure experiences, preferences, and
perceptions that affect satisfaction with treatment.12 A highly
satisfied patient may reflect positive impacts of aesthetic pro-
cedures, such as improved self-image and self-esteem.13-16 It
has been noted that the desire to improve self-image is a key
motivator for deciding to undergo an aesthetic procedure,17
and a survey by the American Society for Dermatologic Sur-
gery lists a desire to appear younger and more attractive
and feel more confident as consumers’ top reasons for seek-
ing aesthetic procedures.18
Injectable hyaluronic acid (HA) fillers are used in aes-
thetic procedures to reduce the appearance of sagging skin
and skin folds by replacing skin HA and increasing the
skin’s water-binding capacity.9 Juvéderm Voluma XC
(Allergan, Inc., Irvine, CA) is an HA gel with lidocaine
approved by the United States (US) Food and Drug Admin-
istration (FDA) for midface volumizing to correct
age-related volume deficit. While products designed with
Hylacross technology (eg, Juvéderm Ultra Plus) comprise
mostly high molecular weight HA, products developed
with the patented Vycross technology, including Juvéderm
Voluma XC, utilize a proprietary mix of low and high mo-
lecular weight HA. Because of their unique composition
and crosslinking process, Vycross-based products maintain
a tightly crosslinked network of HA chains. Consequently,
such products are less hygroscopic than Hylacross
technology-based fillers, and exhibit minimal gel swelling.19
In addition, Vycross technology allows for products with
varied HA concentrations and physicochemical properties
tailored to different indications. Together, these features
help to provide lasting clinical duration despite the reduced
concentration of HA.19 A pivotal, single-blind, randomized,
controlled study demonstrated the safety and effectiveness
of Juvéderm Voluma XC for treatment of midface volume
deficit (MVD).20 Primary effectiveness results were based
on assessments of overall MVD on the validated 6-point
Allergan Mid-Face Volume Deficit Scale (MFVDS). In this
study, 85.6% of patients treated with Juvéderm Voluma XC
improved by 1 point or more on the MFVDS at month 6
(primary endpoint), and the difference in responder rates
between the Juvéderm Voluma XC treatment group and a
no-treatment control group was statistically significant (P
< .001). Correction of MVD with Juvéderm Voluma XC
lasted for up to 2 years.
The objectives of the current analysis were to examine
patient-reported outcomes from the pivotal clinical study
designed to assess the safety and effectiveness of Juvéderm
Voluma XC for the treatment of MVD.
METHODS
Study Design
A multicenter, single-blind, randomized, controlled study
was conducted at 15 sites in the US and Canada from
August 2009 to June 2012. Inclusion and exclusion criteria
were previously reported.20 Briefly, the study enrolled pa-
tients 35 to 65 years of age who desired cheek augmenta-
tion to correct moderate, significant, or severe age-related
MVD. Patients who had undergone cosmetic facial plastic
surgery (other than rhinoplasty more than 2 years before
enrollment), tissue grafting, or tissue augmentation with
silicone, fat, or permanent or semipermanent fillers, as well
as those who planned to undergo such procedures during
the study timeframe, were excluded.
Patients were randomized to 20 mg/mL Juvéderm Voluma
XC (n= 235) or to a no-treatment control (n= 47). A
no-treatment control was chosen because there were no
products approved by the US FDA for an age-related
MVD-treatment indication that could serve as an injection
control. As each subsequent patient qualified for study
entry, the investigator contacted Allergan for treatment as-
signment based on a previously generated randomization
schedule. Control patients received treatment after month 6
(ie, after the primary study endpoint evaluation). Initial
treatment was followed by an optional touch-up 1 month
later if optimal cheek augmentation was not achieved
based on investigator and patient assessment. Areas of
treatment included the zygomaticomalar region, the antero-
medial cheek, and the submalar region (Figure 1).20,21 The
study protocol was registered at www.clinicaltrials.gov
(NCT00978042) and was approved by applicable institu-
tional review boards (ie, Quorum Review IRB, Seattle, WA;
Saint Louis University, St. Louis, MO; The University of
Texas Southwestern Medical Center at Dallas IRB, Dallas,
TX). All patients provided written informed consent prior
to any study-related procedures.
Response Measures and Statistics
Outcome Measures
The following assessments were completed by patients in the
treatment group at baseline and every 3 months for 2 years
after the last treatment: the Global Aesthetic Improvement
Scale (GAIS), satisfaction with midfacial regions, and treat-
ment goals assessment. Patients rated overall aesthetic im-
provement on the GAIS by comparing their appearance at
follow-up visits against 3-dimensional digital (Vectra 3D
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Surface Imaging System, Canfield Scientific, Fairfield, NJ).
photographs taken before treatment on a 5–point scale
ranging from much improved to much worse.22 Patients also
rated level of satisfaction on a scale from 0 to 4 (0, not at all
satisfied; 4, completely satisfied) for each of the following
midface regions: outer and lower cheek areas, prominence or
projection of cheek bones, area on either side of nose, tear
troughs (area under lower eyelids), and nasolabial folds (area
between corners of nose and corners of mouth). Patients set
treatment goals before treatment and, at all follow-up visits,
assessed whether their treatment goals had been met.
Patients in the treatment group completed the following
assessments at baseline and at 1, 6, 12, 18, and 24 months
after the last treatment: overall satisfaction with facial ap-
pearance, Look and Feel of the Midface (LAFM), and Self-
Perception of Age (SPA). Overall satisfaction with facial
appearance was assessed with a questionnaire comprising
11 items rated on a 5-point scale from 0 (not at all, never, or
no, depending upon the question) to 4 (completely, always,
definitely). For the LAFM assessment, patients evaluated
their level of concern about the look and feel of their
cheeks while relaxed and in motion on an 11-point Likert
scale from 0 (not at all) to 10 (very much); this 9-item ques-
tionnaire was patterned after the Facial Lines Outcomes
(FLO-11)23-25 and Look and Feel questionnaires.26 The SPA,
a single-item validated questionnaire, was used to assess
whether patients felt they looked their chronological age,
looked younger, or looked older, and, if applicable, the
number of years younger or older they felt they looked.23,24,26
Safety
Using diaries, patients in the treatment and control groups
reported the presence, location, severity, and duration of
any common treatment-site responses (CTRs) for 30 days
after each treatment.
Statistics
Compared with baseline (pretreatment) scores, a mean im-
provement of 3 points on the LAFM or a statistically signifi-
cant improvement (demonstrated by a lower confidence
limit of the change in mean score greater than 0) in mean
posttreatment satisfaction with facial appearance score
were considered clinically significant. Overall patient satis-
faction with facial appearance scores was calculated as the
mean score from the responses to the 6 questions multi-
plied by 25, resulting in a scale from 0 (least satisfaction) to
100 (greatest satisfaction). Summary tables and descriptive
statistics were used in the presentation of results.
All effectiveness results are reported for patients in the
treatment group. Patients in the control group did not
Figure 1. Diagram showing the midface treatment areas.
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perform self-assessments during the first 6-month period of
the study, as they were aware that they had not received
treatment and were thus not blinded to treatment condition.
RESULTS
Patients
Demographic data for the treatment group are summarized
in Table 1. Patients in the treatment group had investigator-
rated baseline MVD of moderate (51.5%), significant (41.7%),
or severe (3.8%).20 Grades on the MFVDS and correspond-
ing key descriptors include: severe (severe concavity, signifi-
cant prominence of bony landmarks), significant (significant
concavity, moderate prominence of bony landmarks), mod-
erate (moderate concavity, mild prominence of bony land-
marks), mild (mild concavity), minimal (flattening in the
zygomaticomalar region, anteromedial cheek, and/or sub-
malar region), and none (fullness in the zygomaticomalar
region, anteromedial cheek, and/or submalar region).20
Demographics for the control group have been previously
reported and were similar to those for the treatment group.20
Injection Volumes
The mean injection volume (both sides of the face) for
initial and touch-up treatments combined was 6.68 mL
(range, 1.2-13.9 mL). The mean injection volume for initial
treatment was 5.09 mL and 1.93 mL for touch-up treatment.
Mean injection volumes for initial and touch-up treatments
combined for the zygomaticomalar region, anteromedial
cheek, and submalar region were 2.39 mL (range, 0.1-7.0
mL), 2.12 mL (range, 0.4-5.7 mL), and 2.42 mL (range,
0.2-10.0 mL), respectively. Both subcutaneous and supra-
periosteal injection planes were used for 67.3%, 54.9%,
and 24.5% of injections in the zygomaticomalar region,
anteromedial cheek, and submalar region, respectively;
the remainder of injections used only 1 of the injection
planes. Additional details of treatment were previously
reported.20
Table 1. Demographic Characteristics


















Figure 2. Percentage of patients who rated themselves as im-
proved or much improved on the Global Aesthetic
Improvement Scale.
Figure 3. Percentage of patients with improved scores
for overall satisfaction with facial appearance since
baseline.
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Effectiveness
Not all patients completed all outcome measurements at all
visits; thus patient numbers vary between assessments. Six
months after treatment, 92.8% of patients rated their
midface volume as improved or much improved on the
GAIS; a majority (79.0%) of patients still provided these
ratings at 2 years (Figure 2). Overall satisfaction with facial
appearance scores improved from baseline in 89.8% of pa-
tients at 6 months and in 75.8% of patients at 2 years
Table 2. Patient Satisfaction With Midfacial Regions
Midfacial Region Percentage (n/N) of Patients Satisfieda
Baseline Month 6 Month 12 Month 24
Outer and lower cheek areas 59.0 (138/234) 97.6 (202/207) 93.1 (188/202) 89.8 (141/157)
Prominence or projection of cheek
bones
69.7 (163/234) 97.6 (204/209) 95.5 (191/200) 91.7 (143/156)
Area on either side of nose 53.6 (125/233) 95.7 (198/207) 94.0 (187/199) 91.0 (142/156)
Tear troughsb 47.2 (110/233) 84.7 (177/209) 80.1 (161/201) 77.7 (122/157)
Nasolabial foldsc 31.2 (73/234) 73.6 (153/208) 69.0 (138/200) 56.7 (89/157)
aPatients who rated scores of 1 (somewhat satisfied), 2 (moderately satisfied), 3 (very satisfied), or 4 (completely satisfied) on a scale of 0 to 4. bArea under lower eyelids. cArea between corners of
nose and corners of mouth.
Figure 4. Percentage of patients rating scores of 7 to 10 on the assessment of the look and feel of the midface. (A) Cheeks make me
look older than I want to look; (B) Cheeks make me look tired, even when I am not; (C) Cheeks make me look unattractive; (D)
Cheeks make me look sad, even when I am not. Scores ranged from 0 to 10, where 0= not at all, 5= somewhat, and 10= very
much. Significant improvements in mean score were noted in all categories at 6 and 12 months and in the categories of older and
tired at 24 months. *Clinically significant change from baseline in mean satisfaction score (defined a priori as change of ≥3 points).
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(Figure 3). At all time points, increases from baseline in
mean scores were statistically significant. The percentage of
patients with improved satisfaction with facial appearance at
month 6 was high across all injection volumes but increased
with greater injection volumes. By injection volume quartile
(initial plus touch-up volume), the percentage of patients
with improved satisfaction was 78.4% for ≤4.6 mL, 89.8%
for 4.6 to ≤6.5 mL, 94.3% for 6.5 to ≤8.9 mL, and 96.2% for
>8.9 mL.
The percentage of patients who were somewhat to
completely satisfied with their outer and lower cheek areas
improved from 59.0% at baseline to 97.6% at 6 months and
remained well above baseline at 12 months (93.1%) and 2
years (89.8%) (Table 2). Satisfaction with cheek-bone pro-
jection improved from 69.7% at baseline to 97.6% at 6
months and was maintained at 91.7% at 2 years. Increases
in patient satisfaction were also noted in regard to untreat-
ed, adjacent midfacial areas (eg, tear troughs, nasolabial
folds, and areas on either side of the nose) (Table 2). For
example, less than half of patients (47.2%) were satisfied
with their tear troughs before MVD treatment. However, at
6 months and 2 years, satisfaction increased to 84.7% and
77.7%, respectively.
At 6 months, more than two-thirds of patients (67.8%)
agreed that their treatment goals had been met. More than
half of patients in the treatment group (58.4%) agreed that
Figure 5. Aesthetic outcomes with Juvéderm Voluma XC for this 48-year-old woman before treatment (A, B), at 6 months (C, D),
and at 24 months (E, F) after treatment with 6.3 mL of Juvéderm Voluma XC in the midface.
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their treatment goals were attained through month 12, and
49.0% of patients still agreed at 2 years.
At baseline, a majority of patients rated their cheeks
as making them look older, tired, unattractive, and sad.
Clinically significant improvements in mean satisfaction
scores (change of ≥3 points in mean satisfaction score
since baseline) were noted for the categories of older and
tired at 6, 12, and 24 months and for the categories of sad
and unattractive at 6 and 12 months (Figure 4). In the 5
additional categories, patients noted both at baseline and
subsequent time points that their cheeks did not feel hard,
lumpy/grainy, or unnatural and did not look uneven or
unnatural.
Representative examples of aesthetic outcomes follow-
ing treatment with Juvéderm Voluma XC are shown in
Figures 5 and 6.
At each time point following treatment with Juvéderm
Voluma XC, a majority of patients perceived themselves as
looking younger versus baseline, from 72.5% at month 6 to
55.4% at month 24 (Figure 7). The mean decrease in per-
ceived age was 4.9 years at month 6, 3.8 years at month 12,
and 3.3 years at month 24.
Figure 6. Aesthetic outcomes with Juvéderm Voluma XC for this 59-year-old woman before treatment (A, B), at 6 months (C, D),
and at 24 months (E, F) after treatment with 8.9 mL of Juvéderm Voluma XC in the midface.
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Patients in the control group who received treatment at
month 6 of the study reported similar improvements in ef-
fectiveness results over time compared with the treatment
group. For example, the percentage of patients in the
control group who rated their midface volume as improved
or much improved on the GAIS was 86.7% at 6 months,
73.1% at 12 months, and 68.4% at 18 months after they re-
ceived treatment.
Safety
For the 265 patients who completed safety diaries after
initial treatment (234 patients in the primary follow-up
period and 31 control patients treated in the extended
follow-up period), the most frequently reported CTRs in
patient diaries were tenderness, swelling, firmness, and
lumps/bumps (Table 3). Most CTRs (80.7%) were mild or
moderate in severity. The duration of CTRs was ≤2 weeks
for 55.4% of patients.
DISCUSSION
These results demonstrate that Juvéderm Voluma XC treat-
ment for age-related MVD has a long-term positive effect on
overall aesthetic look, patient satisfaction, and perception
of appearance. A majority of patients were highly satisfied
across a number of different measures, with more than
75% of treated patients completely satisfied with overall
facial appearance for up to 2 years. Patients also perceived
themselves to appear younger than their chronological age.
These results were also reflected in the attainment of treat-
ment goals and indicate that individuals seeking treatment
with Juvéderm Voluma XC are likely to achieve the younger
midface appearance they desire.
Figure 7. Percentage of patients reporting that their perceived age was younger than their chronological age, older, or the same
compared with baseline at 6 (A), 12 (B), and 24 (C) months after treatment.
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There are a limited number of published studies focus-
ing on patient-reported outcomes with volumizing HA
fillers. High levels of patient-reported improvement on the
GAIS regarding the use of volumizing HA fillers for MVD
have been previously reported.22,27,28 Authors studying
volumizing HA fillers have also reported patient satisfac-
tion, patient likelihood of returning for additional treat-
ment, and patient willingness to recommend treatment to
friends.22,27,29,30 The current study is unique in that the
authors report on multiple patient-reported outcome mea-
sures to fully assess facial aesthetic outcomes from the pa-
tient’s perspective.
A clinically significant response in facial aesthetics
can support treatment satisfaction, providing further evi-
dence of successful outcomes from the patient’s perspec-
tive. In this study, a clinically significant response refers
to the point at which patients perceive and report mean-
ingful improvements in their midface volume. Based on
predefined criteria, the authors of the current study
found that patients treated with Juvéderm Voluma XC
perceived clinically significant improvement in the look
and feel of their midface and also experienced a clinically
significant increase in overall satisfaction with their
facial appearance.
In addition to high rates of satisfaction with treated mid-
facial regions, increases in patient satisfaction were also ob-
served in untreated areas of the midface, including the tear
troughs, the nasolabial folds, and areas on either side of the
nose. These observations are likely associated with the
impact of midface refilling on the surrounding anatomy.
For example, adding filler to the midface may restore struc-
tural support to the medial cheek compartment, reducing
the prominence of tear troughs and the nasolabial folds.
Thus, the benefits of treatment are not centered on the
exact area of injection but extend in a multitiered fashion.
One limitation of this study is that not all of the patient-
reported outcomeswere validated. Further, clinical significance
is largely a qualitative assessment, and predefined criteria
for the determination of clinical significance were subjec-
tive. Because patients were not blinded with regard to treat-
ment, the outcomet measures may have been slightly
biased. However, it should be noted that patient-rated im-
provement on the GAIS at 6 months was consistent with
blinded investigator ratings at this time point (with 82.2%
of investigators and 92.8% of patients rating midface
volume as improved or much improved at 6 months), as
previously reported.20 Another limitation was the lack of
blunt cannula use, as the researchers employed a variety
of injection techniques using needles to inject into the sub-
cutaneous and supraperiosteal planes. Additional study is
required to determine the safety and effectiveness of
Juvéderm Voluma XC injection administered via blunt can-
nulae vs needles. The authors of the current study did not
compare Juvéderm Voluma XC with another filler. This
limitation underscores the lack of an agreed-upon standard
for midfacial filling; given that there is no US FDA-approved
filler for the midface other than Juvéderm Voluma XC, the
closest standard would be fat injection, which is a surgical
alternative.
The safety profile observed in this study was comparable
to that of other fillers.28,31 CTRs were minor and of short
duration.
CONCLUSIONS
High patient satisfaction and improvements in self-image
may be the most essential outcomes and motivators for
facial aesthetic procedures. On multiple measures, patients
treated with Juvéderm Voluma XC for age-related MVD ex-
perienced improved satisfaction with their midface and
overall facial aesthetic look and appearance for up to 2
years after treatment.
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Tenderness 92.1 96.3 88.5
Swelling 85.7 90.3 91.6
Firmness 82.3 92.2 76.6
Lumps/bumps 81.1 90.2 66.0
Bruising 77.7 88.9 85.0
Pain 66.4 97.7 97.2
Redness 66.0 96.0 96.0
Discoloration 41.1 89.9 89.9
Itching 38.5 89.2 100
aN denotes the number of patients who completed the diary after initial treatment. bThe
denominator for percentages is the number of patients who reported an incidence of that
treatment response in the diary.
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